Highlights from the Co-Creating Impact Summit 2020

The third annual Co-Creating Impact Summit in collaboration with Novartis’ Impact Valuation Advisory Council – chaired by John Elkington – brought together internal and external thought leaders in the area of ESG, sustainability and impact valuation to discuss and debate on the current status, future perspectives and ways Novartis could be best prepared for the future. 

The hugely successful event with over 1’100 registrations reflected on the most pressing topics around Investors and Sustainability, Climate and Health, the Future of Integrated Reporting, the Role of Governments, and …

/by

New Zolgensma data demonstrate age-appropriate development when used early, real-world benefit in older children and durability 5+ years post-treatment

  • Children with SMA treated presymptomatically achieved age-appropriate motor milestones including sitting, standing and walking; required no ventilatory or feeding tube support; and had no serious, treatment-related adverse events
  • Real-world data indicate older children (aged ≥6 months) achieved clinically meaningful benefit with Zolgensma alone, after or in combination with another SMA therapy, with events consistent with the previously described safety profile
  • Zolgensma led to achievement of new milestones years after …
/by